Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | MGAM | O43451 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.41 |
| ▸ | CFTR | P13569 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2135495 | 1.00 | SLC6A4 (0.52) | SLC6A4MGAMFFAR1RAB9AKDM1A | |
| SCHEMBL2135499 | 1.00 | SLC6A4 (0.52) | SLC6A4MGAMFFAR1RAB9AKDM1A | |
| SCHEMBL2777948 | 0.83 | SLC6A4 (0.51) | SLC6A4MGAMRAB9AKDM1AMAOA | |
| SCHEMBL1225412 | 0.83 | ALDH1A1 (0.58) | SLC6A4MGAMKDM1AMAOAMAOB | |
| SCHEMBL12049549 | 0.81 | FFAR1 (0.46) | FFAR1RAB9A | |
| SCHEMBL3585897 | 0.81 | FFAR1 (0.46) | FFAR1RAB9A | |
| SCHEMBL2136056 | 0.80 | SLC6A4 (0.51) | SLC6A4MGAMRAB9ALMNASMN1; SMN2 | |
| SCHEMBL4728893 | 0.80 | GRM1 (0.51) | SLC6A4MGAMRAB9ALMNASMN1; SMN2 | |
| SCHEMBL2136050 | 0.80 | SLC6A4 (0.51) | SLC6A4MGAMRAB9ALMNASMN1; SMN2 | |
| SCHEMBL15799376 | 0.80 | SLC6A4 (0.51) | SLC6A4MGAMRAB9ALMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9101616-B2 | Aryl substituted carboxamide derivatives as calcium or sodium channel blockers | RAQUALIA PHARMA INC. (JP) | 2015-08-11 | — | — | US | disclosed |
| US-20120101105-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101105-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | CACNA1I, CACNA1G, CACNA1H | SLC6A4 244/4885MGAM 4722/4885FFAR1 1470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.